{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:19:42Z","timestamp":1791037182719,"version":"4.1.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,7,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Therapy of relapsed pediatric acute lymphoblastic leukemia (ALL) is hampered by low remission rates and high toxicity, especially in second and subsequent relapses. Our phase 1 study, T2005-003, showed that the combination of bortezomib with vincristine, dexamethasone, pegylated asparaginase, and doxorubicin had acceptable toxicity. We report the phase 2 expansion of this combination in patients with relapsed ALL who failed 2-3 previous regimens. Twenty-two patients with relapsed ALL were treated with bortezomib combined with this regimen; their ages ranged from 1 to 22 years, and they had either B-precursor ALL (n = 20) or T-cell ALL (n = 2). Grade 3 peripheral neuropathy developed in 2 (9%) patients. After 3 patients died from bacterial infections, treatment with vancomycin, levofloxacin, and voriconazole prophylaxis resulted in no further infectious mortality in the last 6 patients. Fourteen patients achieved complete remission (CR), and 2 achieved CR without platelet recovery, for an overall 73% response rate, meeting predefined criteria allowing for early closure. B-precursor patients faired best, with 16 of 20 (80%) CR + CR without platelet recovery, whereas the 2 patients with T-cell ALL did not respond. Thus, this combination of bortezomib with chemotherapy is active in B-precursor ALL, and prophylactic antibiotics may be useful in reducing mortality. Bortezomib merits further evaluation in combination therapy in pediatric B-precursor ALL. This study is registered at http:\/\/www.clinicaltrials.gov as NCT00440726.<\/jats:p>","DOI":"10.1182\/blood-2012-04-418640","type":"journal-article","created":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:58:26Z","timestamp":1338512306000},"page":"285-290","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":193,"title":["Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia &amp; Lymphoma (TACL) Study"],"prefix":"10.1182","volume":"120","author":[{"given":"Yoav H.","family":"Messinger","sequence":"first","affiliation":[{"name":"Children's Hospitals and Clinics of Minnesota, Hematology\/Oncology, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Gaynon","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA;"},{"name":"Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sposto","sequence":"additional","affiliation":[{"name":"Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA; and"},{"name":"Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"van der Giessen","sequence":"additional","affiliation":[{"name":"Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Eckroth","sequence":"additional","affiliation":[{"name":"Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemily","family":"Malvar","sequence":"additional","affiliation":[{"name":"Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce C.","family":"Bostrom","sequence":"additional","affiliation":[{"name":"Children's Hospitals and Clinics of Minnesota, Hematology\/Oncology, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111808351399300_B1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2005.05773.x","article-title":"Childhood acute lymphoblastic leukaemia and relapse.","volume":"131","author":"Gaynon","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111808351399300_B2","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2009.22.2950","article-title":"Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.","volume":"28","author":"Ko","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111808351399300_B3","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-03-0508","article-title":"Phase I study of bortezomib in refractory or relapsed acute leukemias.","volume":"10","author":"Cortes","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111808351399300_B4","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1158\/1078-0432.CCR-06-2173","article-title":"A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.","volume":"13","author":"Horton","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111808351399300_B5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-005-0135-z","article-title":"Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.","volume":"58","author":"Horton","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2019111808351399300_B6","first-page":"203","article-title":"Morphoproteomics and bortezomib\/dexamethasone-induced response in relapsed acute lymphoblastic leukemia.","volume":"34","author":"Brown","year":"2004","journal-title":"Ann Clin Lab Sci"},{"issue":"2","key":"2019111808351399300_B7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.22456","article-title":"Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.","volume":"55","author":"Messinger","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"2019111808351399300_B8","unstructured":"Cancer Therapy Evaluation Program.\n          CTCAE criteria\n          Accessed June 4, 2012\n          Version 3.0. http:\/\/ctep.cancer.gov"},{"issue":"411","key":"2019111808351399300_B9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/01621459.1990.10474929","article-title":"Construction of permutation tests.","volume":"85","author":"Welch","year":"1990","journal-title":"J Am Stat Assoc"},{"key":"2019111808351399300_B10","volume-title":"Velcade Prescribing Information","author":"Millennium Pharmaceuticals I","year":"2010"},{"issue":"24","key":"2019111808351399300_B11","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","article-title":"Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: a Children's Oncology Group Study [corrected].","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111808351399300_B12","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/ajh.21855","article-title":"Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial.","volume":"85","author":"Eleutherakis-Papaiakovou","year":"2010","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111808351399300_B13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/cncr.23563","article-title":"Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia.","volume":"113","author":"Kurt","year":"2008","journal-title":"Cancer"},{"issue":"10","key":"2019111808351399300_B14","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111808351399300_B15","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1056\/NEJMoa050078","article-title":"Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.","volume":"353","author":"Cullen","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111808351399300_B16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/10428190600988010","article-title":"Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone.","volume":"48","author":"Chew","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2019111808351399300_B17","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1182\/blood-2005-11-4541","article-title":"Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.","volume":"107","author":"Miyakoshi","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111808351399300_B18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/01.mjt.0000245224.20913.0d","article-title":"Severe pulmonary complications in African-American patient after bortezomib therapy.","volume":"13","author":"Ohri","year":"2006","journal-title":"Am J Ther"},{"issue":"7","key":"2019111808351399300_B19","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.leukres.2006.09.015","article-title":"Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?","volume":"31","author":"Pitini","year":"2007","journal-title":"Leuk Res"},{"issue":"6","key":"2019111808351399300_B20","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","article-title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.","volume":"144","author":"Richardson","year":"2009","journal-title":"Br J Haematol"},{"issue":"19","key":"2019111808351399300_B21","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2005.04.5856","article-title":"Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.","volume":"24","author":"Gaynon","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111808351399300_B22","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.3109\/10428194.2011.593271","article-title":"Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-kappaB activity.","volume":"52","author":"Hu","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"2019111808351399300_B23","doi-asserted-by":"crossref","first-page":"9946","DOI":"10.1073\/pnas.1334037100","article-title":"Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.","volume":"100","author":"Lee","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"2019111808351399300_B24","doi-asserted-by":"crossref","first-page":"14374","DOI":"10.1073\/pnas.202445099","article-title":"Molecular sequelae of proteasome inhibition in human multiple myeloma cells.","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111808351399300_B25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.leu.2404444","article-title":"Proteasome inhibitors: antitumor effects and beyond.","volume":"21","author":"Nencioni","year":"2007","journal-title":"Leukemia"},{"issue":"13","key":"2019111808351399300_B26","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/jnci\/djr160","article-title":"Novel proteasome inhibitors to overcome bortezomib resistance.","volume":"103","author":"Ruschak","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"5-6","key":"2019111808351399300_B27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","article-title":"Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.","volume":"15","author":"Dick","year":"2010","journal-title":"Drug Discov Today"},{"issue":"5","key":"2019111808351399300_B28","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"issue":"21","key":"2019111808351399300_B29","doi-asserted-by":"crossref","first-page":"16096","DOI":"10.1074\/jbc.M109.072694","article-title":"Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.","volume":"285","author":"Li","year":"2010","journal-title":"J Biol Chem"},{"issue":"14","key":"2019111808351399300_B30","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/onc.2010.566","article-title":"NF-kappaB addiction and its role in cancer: \u2018one size does not fit all\u2019.","volume":"30","author":"Chaturvedi","year":"2011","journal-title":"Oncogene"},{"issue":"3","key":"2019111808351399300_B31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1158\/1535-7163.MCT-10-0777","article-title":"AMPK and Akt determine apoptotic cell death after perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia.","volume":"10","author":"Kuznetsov","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2019111808351399300_B32","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/leu.2011.50","article-title":"GSI-I (Z-LLNle-CHO) inhibits gamma-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.","volume":"25","author":"Meng","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"2019111808351399300_B33","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-2141.2011.08671.x","article-title":"Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network.","volume":"153","author":"Uckun","year":"2011","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/2\/285\/1360542\/zh802812000285.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/2\/285\/1360542\/zh802812000285.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T08:59:00Z","timestamp":1574067540000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/2\/285\/30407\/Bortezomib-with-chemotherapy-is-highly-active-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,12]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,7,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-04-418640","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717957011.793461504","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,12]]}}}